ABUS:NSD-Arbutus Biopharma Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.07

Change

0.00 (0.00)%

Market Cap

USD 0.30B

Volume

1.99M

Average Target Price

USD 7.33 (+138.87%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD68.41B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.78B 21.32 15.54
REGN Regeneron Pharmaceuticals, Inc

N/A

USD53.84B 16.47 12.24
BNTX BioNTech SE

N/A

USD36.60B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD36.16B 60.18 35.79
BGNE BeiGene, Ltd

N/A

USD28.44B N/A N/A
SGEN Seagen Inc

N/A

USD26.38B 43.18 34.88
RPRX Royalty Pharma plc

N/A

USD25.42B 22.60 15.19
GMAB Genmab A/S

N/A

USD22.94B 26.59 3.31
CVAC CureVac N.V

N/A

USD20.43B N/A N/A

ETFs Containing ABUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.52% 34% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.52% 34% F 15% F
Trailing 12 Months  
Capital Gain 157.98% 84% B 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 157.98% 84% B 82% B-
Trailing 5 Years  
Capital Gain -37.35% 40% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.35% 40% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 26.51% 60% D- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.51% 60% D- 75% C
Risk Return Profile  
Volatility (Standard Deviation) 81.47% 36% F 19% F
Risk Adjusted Return 32.54% 58% F 54% F
Market Capitalization 0.30B 44% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.44 77% C+ 59% F
Price / Cash Flow Ratio -5.82 42% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.97% 41% F 17% F
Return on Invested Capital -65.56% 37% F 13% F
Return on Assets -29.51% 43% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.30 59% F 48% F
Short Percent 5.31% 59% F 37% F
Beta 2.93 4% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector